Dog Pemphigus Treatment Monitoring

Treating pemphigus autoimmune skin disease requires careful immunosuppressive dosing and monitoring to balance disease control with treatment side effects.

Key Facts

Prednisone is typically started at immunosuppressive doses of 2-4 mg/kg per day for pemphigus
Azathioprine, cyclosporine, or mycophenolate are added as steroid-sparing agents
Treatment monitoring includes skin lesion assessment, blood counts, and biochemistry for drug effects
Azathioprine can cause bone marrow suppression requiring CBC monitoring every 2-4 weeks
Cyclosporine levels should be measured to ensure therapeutic drug concentrations
Remission rates vary - some dogs achieve complete remission allowing medication withdrawal
Relapse requires prompt recognition and treatment escalation before lesions become extensive

Welfare Considerations

Pemphigus treatment involves prolonged immunosuppression with significant side effect potential. Polydipsia, polyuria, and weight gain from corticosteroids cause discomfort and altered behavior. Bone marrow suppression from azathioprine creates infection risk. Finding the minimum effective dose that maintains remission while minimizing side effects is the welfare optimization goal. Dogs in well-controlled pemphigus with minimum medication enjoy good quality of life despite their chronic disease.

What You Can Do

Follow monitoring schedules exactly - blood tests at recommended intervals detect drug toxicity before clinical signs
Keep skin lesion photographic records to objectively track disease activity and treatment response
Report new lesions promptly - early relapses are easier to control than established disease
Discuss steroid-sparing agents with your dermatologist to reduce long-term steroid exposure
Maintain all scheduled rechecks even when dogs appear to be doing well on treatment
Connect with pemphigus support communities for shared experience managing this challenging condition